Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2013 · 10-Q
Revenue$37.25M$37.25M+33.9% vs Q2 2012 Net Income-$883.00K-$883.00KN/M vs Q2 2012 EPS Diluted-$0.06-$0.06N/M vs Q2 2012 Gross Profit$6,849,000+4.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,796,000N/M Free Cash Flowderived-$2,307,000N/M Margins · derivedGross margin18.4%−5.2 pt vs Q2 2012
Operating margin-2.3%−1.1 pt vs Q2 2012
Net margin-2.4%−0.8 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 5, 2013 · 36 d after period end